Unknown

Dataset Information

0

Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).


ABSTRACT: BACKGROUND:Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function. We have therefore re-evaluated the clinical effect of combination therapy (salmeterol plus fluticasone) in moderate-to-severe COPD, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI) and trial data from Towards a Revolution in COPD Health (TORCH). METHODS:Of the 6112 TORCH participants, 5688 (93.1%) had GLI-based moderate-to-severe COPD (mean age 64.8 years). The primary outcome was all-cause mortality and the primary comparison was combination therapy vs. placebo. Secondary outcomes included COPD and cardiovascular (CV) mortality and pneumonia. A modified intention-to-treat analysis evaluated differences in time-to-event over a three-year period, using Cox proportional hazards models with statistical significance at p?

SUBMITTER: Vaz Fragoso CA 

PROVIDER: S-EPMC6519718 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).

Vaz Fragoso Carlos A CA   Gill Thomas M TM   Leo-Summers Linda S LS   Van Ness Peter H PH  

Respiratory medicine 20190329


<h4>Background</h4>Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function. We have therefore re-evaluated the clinical effect of combination therapy (salmeterol plus fluticasone) in moderate-to-severe COPD, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI) and trial data from To  ...[more]

Similar Datasets

| PRJNA647843 | ENA
2016-05-25 | GSE77344 | GEO
| PRJEB46960 | ENA
| S-EPMC3651866 | biostudies-literature
| S-EPMC8504989 | biostudies-literature
2008-05-31 | GSE8581 | GEO
2003-07-16 | GSE475 | GEO
2022-10-17 | PXD035120 | Pride
| S-EPMC5732734 | biostudies-literature